M&T Bank Corp Viking Therapeutics, Inc. Transaction History

M&T Bank Corp

$30.1 Billion
Q3 2024

A detailed history of M&T Bank Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 5,593 shares of VKTX stock, worth $182,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,593

Previous 5,593 -0.0%

Holding current value

$182,611

Previous $354,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$49.84 - $70.47 $278,755 - $394,138	5,593 New	5,593 $354,000
Q1 2022 May 09, 2022	SELL	$3.0 - $4.88 $85,944 - $139,802	-28,648 Closed	0 $0
Q4 2021 Feb 07, 2022	SELL	$4.6 - $6.72 $8,615 - $12,586	-1,873 Reduced 6.14%	28,648 $132,000
Q3 2021 Oct 28, 2021	SELL	$5.58 - $7.04 $1,891 - $2,386	-339 Reduced 1.1%	30,521 $192,000
Q1 2021 May 06, 2021	SELL	$5.74 - $9.67 $15,652 - $26,370	-2,727 Reduced 8.12%	30,860 $195,000
Q4 2020 Feb 12, 2021	BUY	$5.3 - $6.71 $53 - $67	10 Added 0.03%	33,587 $190,000
Q3 2020 Nov 06, 2020	BUY	$5.73 - $8.11 $41,754 - $59,097	7,287 Added 27.72%	33,577 $196,000
Q2 2020 Jul 29, 2020	SELL	$4.35 - $8.08 $221 - $412	-51 Reduced 0.19%	26,290 $190,000
Q1 2020 May 14, 2020	BUY	$3.45 - $7.95 $4,253 - $9,802	1,233 Added 4.91%	26,341 $123,000
Q4 2019 Feb 07, 2020	BUY	$6.38 - $8.73 $20,339 - $27,831	3,188 Added 14.54%	25,108 $201,000
Q3 2019 Nov 12, 2019	BUY	$6.55 - $8.6 $8,384 - $11,008	1,280 Added 6.2%	21,920 $151,000
Q2 2019 Aug 12, 2019	SELL	$7.67 - $10.63 $1,273 - $1,764	-166 Reduced 0.8%	20,640 $171,000
Q1 2019 May 15, 2019	BUY	$7.58 - $9.94 $157,709 - $206,811	20,806 New	20,806 $207,000

Others Institutions Holding VKTX

# of Institutions

476

Shares Held

63.4M

Call Options Held

5.76M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.5B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account